HeartSine® was founded in 1997 for the purpose of developing a family of products
focused on an emerging growth segment of the medical device marketplace: easy-to-use,
affordable defibrillators for the home and public access markets. HeartSine® established
R&D activities in Northern Ireland and initiated a formal collaboration with the
University of Ulster’s Bioengineering Centre (NIBEC) and its partner, the Royal Victoria
Hospital (RVH), a local teaching and research hospital, to augment and enhance our
in-house development activities. HeartSine’s engineering team has focused on developing
leading edge, innovative technology systems for defibrillators.
HeartSine’s technology and innovation is based on a proven history of development
in the field of cardiac defibrillation that began in the 1960s. Our R&D is spearheaded
by the best technology experts in the industry. Our Chief Technology Officer is Professor
John Anderson who was pivotal in the groundbreaking work that created the world’s
first mobile coronary care unit. Professor Anderson has been miniaturizing defibrillators
for four decades. He has been a cornerstone in developing HeartSine’s state-of-the-art
Samaritan® PAD Public Access Defibrillator.
Also steering their research is a leading authority in the field of clinical cardiac
research, Dr. Jennifer Adgey.